Clinical Trial Update: Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating vildagliptin 100 mg once daily as add-on therapy to metformin versus placebo in adults with type 2 diabetes inadequately controlled o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Vildagliptin (Galvus) (vildagliptin)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED